UNSPSC 51273009: Remifentanil

This classification denotes an opioid receptor agonist and opioid with the molecular formula C20H28N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P10582JYYK, chemically known as 1-piperidinepropanoic acid, 4-(methoxy-carbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester but generally known as remifentanil, which bears US NIH Compound Identifier 60815. European Medicines Agency schedules Remifentanil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10272MIG.

UNSPSC 51273009 Remifentanil is a Commodity code that nominally identifies a specific opioid pharmaceutical, but recent state and local procurement activity under this code does not reflect direct purchase of remifentanil itself. Instead, soliciting bodies are acquiring a broader mix of pharmaceutical products and pharmacy benefit management services — including naloxone, over-the-counter medications, and direct-to-manufacturer prescription fulfillment capabilities. The code shows limited recent relevant activity; the three opportunities posted between January and June 2026 span naloxone procurement through traditional competitive bidding, generic pharmaceutical supply through cooperative purchasing, and exploratory market inquiry into pharmacy program restructuring. The issuing bodies include a county health department (Seminole County, Florida), a state health and human services agency (Texas HHS Commission), and a multistate cooperative purchasing alliance (MMCAP, administered by the Minnesota Department of Administration). This fragmentation suggests that pharmaceutical procurement under this taxonomy does not consolidate around a single agency or procurement model at the state and local level.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County's IFB60459723LAS, posted June 30, 2026 with a July 26, 2023 response deadline, solicited 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive sealed bids, with quarterly delivery to the Seminole County Community Health Building in Sanford. The Texas HHS Commission issued RFI HHS0017013 in April 2026 to gather vendor capability information for a direct-to-manufacturer prescription program without committing to award or budget yet. MMCAP released RFP S1070000015802 in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon through three authorized wholesalers, with contract effectiveness July 1, 2026. The code shows little recent procurement activity specifically targeting remifentanil; potential vendors should clarify whether they are pursuing broader pharmaceutical distribution or whether this code reflects a taxonomy misalignment in the source data.